Search results for "Hepatocellular"

showing 10 items of 885 documents

Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis.

1998

Objective This study compares the results of liver transplantation (LTx) and liver resection (LR) for hepatocellular carcinoma (HCC) to test the widespread hypothesis that LTx is the preferable approach for small HCCs. Summary Background Data With respect to scarcity of donor organs and poor results, LTxs for large HCCs are obsolete. Small HCC transplantations have been reported to result in an excellent survival rate. However, the data of comparative studies are controversial. Methods Patients who were treated curatively by LTx (n = 50) or LR (n = 52) for HCC were included in this retrospective study. Survival and freedom from recurrence were analyzed. Patients were stratified according to…

AdultMalemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentLiver transplantationGastroenterologyDisease-Free SurvivalResectionText miningInternal medicinemedicineHepatectomyHumansSurvival rateAgedRetrospective Studiesbusiness.industryLiver NeoplasmsRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryLiver TransplantationTransplantationSurvival RateHepatocellular carcinomaSurgeryFemaleNeoplasm Recurrence LocalbusinessResearch Article
researchProduct

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

2004

Background: The key end point for treatment efficacy in chronic hepatitis C is absence of detectable virus at six months after treatment. However, the incidence of clinical events during long term follow up of patients with sustained virological response is still poorly documented and may differ between the Eastern and Western world. Aims: To assess clinical end points during long term follow up of European patients with a sustained virological response to interferon monotherapy. Methods: Meta-analysis of individual patient data from eight European protocolled follow up studies of interferon treatment for chronic hepatitis C. Results: A total of 286 sustained virological responders and 50 b…

AdultMalemedicine.medical_specialtyPlus ribavirinCirrhosisHepatocellular-CarcinomaAdolescentFibrosiPopulationAlpha interferonAntiviral AgentsSDG 3 - Good Health and Well-beingInternal medicinemedicineHumansDecompensationeducationSurvival analysisAgededucation.field_of_studyCirrhosibusiness.industryIncidence (epidemiology)Follow-upNatural-historyGastroenterologyCohortHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseSurvival AnalysisImpactTreatment OutcomeLiverHepatocellular carcinomaImmunologyRegression AnalysisFemaleTherapyInterferonsbusinessAlpha-interferonGut
researchProduct

A Novel APOB Mutation Identified by Exome Sequencing Cosegregates With Steatosis, Liver Cancer, and Hypocholesterolemia

2013

Objective— In familial hypobetalipoproteinemia, fatty liver is a characteristic feature, and there are several reports of associated cirrhosis and hepatocarcinoma. We investigated a large kindred in which low-density lipoprotein cholesterol, fatty liver, and hepatocarcinoma displayed an autosomal dominant pattern of inheritance. Approach and Results— The proband was a 25-year-old female with low plasma cholesterol and hepatic steatosis. Low plasma levels of total cholesterol and fatty liver were observed in 10 more family members; 1 member was affected by liver cirrhosis, and 4 more subjects died of either hepatocarcinoma or carcinoma on cirrhosis. To identify the causal mutation in this f…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BNonsense mutationBiologyArticlehypobetaliproteinemia type 1Hypobetalipoproteinemiasexome fatty liver hypobetalipoproteinemia familial 2Young Adultsymbols.namesakeInternal medicinemedicineHumansExomeHEPATOCELLULAR CARCINOMAExomeExome sequencingApolipoproteins Bfatty liverFamily HealthGeneticsSanger sequencingLiver NeoplasmsFatty liverMiddle AgedHEPATOCELLULAR CARCINOMA; exome; fatty liver; hypobetaliproteinemia type 1medicine.diseasePedigreeFatty LiverHypocholesterolemiaCholesterolEndocrinologyCodon Nonsensebiology.proteinsymbolsFemaleCardiology and Cardiovascular MedicineLiver cancerexomeArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Impact of Extended-Criteria Donor Liver Grafts on Benchmark Metrics of Clinical Outcome After Liver Transplantation: A Single Center Experience.

2020

Abstract Background The adoption of extended criteria for donors remains the best strategy to widen the pool of available liver graft against the chronic shortage of donors. Benchmarking in liver transplantation (LT) offers the unprecedented opportunity to compare clinical outcome measures to a set of validated reference values. We aimed to evaluate the impact of marginal grafts usage in a cohort of low-risk benchmark cases from an area with a very low rate of deceased donation. Methods A cohort of low-risk benchmark cases was identified from all adult patients who underwent LT at our center. Among these patients, those transplanted with a graft from an extended-criteria donor (ECD) were id…

AdultMalemedicine.medical_specialtymedicine.medical_treatment030230 surgeryLiver transplantationSingle Centerlaw.inventionDonor Selection03 medical and health sciences0302 clinical medicinePostoperative ComplicationslawRisk FactorsmedicineLiving DonorsHumansRetrospective StudiesTransplantationDonor selectionbusiness.industryIncidenceGraft SurvivalPostoperative complicationRetrospective cohort studyMiddle Agedmedicine.diseasePrognosisIntensive care unitSurgeryLiver TransplantationBenchmarkingHepatocellular carcinomaCohort030211 gastroenterology & hepatologySurgeryFemalebusinessTransplantation proceedings
researchProduct

Infection with human herpes virus type 8 in an area at high prevalence for hepatitis C virus infection in southern Italy

2004

Summary.  The Campania Region is a geographical area of southern Italy characterized by high incidence rates of hepatocellular carcinoma and of classic Kaposi's sarcoma. Epidemiological investigations carried out among different population groups in this region have found high prevalence rates of both hepatitis C virus (HCV) and human herpesvirus type 8 (HHV-8). To assess co-infection rates of HCV and HHV-8, we carried out a cross-sectional seroepidemiological study prevalence in Pomigliano d'Arco, a Health District of Campania located 20 km away from Naples. The overall rate of HCV/HHV-8 co-infection was 3.1%, 3.5% among men and 2.7% among women. No difference emerged in the HCV/HHV-8 co-i…

AdultMalemedicine.medical_specialtyvirusesHepatitis C virusPopulationAntibodies Viralmedicine.disease_causeSeroepidemiologic StudiesVirologyEpidemiologyHumansMedicineeducationAgededucation.field_of_studyHigh prevalenceHepatologybusiness.industryTransmission (medicine)Human herpes virusPublic healthvirus diseasesHerpesviridae InfectionsHepatitis C AntibodiesMiddle Agedmedicine.diseaseHepatitis CVirologyCross-Sectional StudiesInfectious DiseasesItalyHepatocellular carcinomaHerpesvirus 8 HumanFemalebusinessJournal of Viral Hepatitis
researchProduct

Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma

2015

Summary What is known and objective Drug eluting beads (DEBs) theoretically improve the efficacy and safety of transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). Nonetheless, their economic profile has not been assessed. Our retrospective before/after study aimed to compare efficacy, safety and economic profile of two strategies of TACE without (Period 1) or with the possibility of using DEBs (Period 2). Methods All HCC patients treated by TACE in our hospital between March 2006 and May 2013 were included. Economic analyses were performed from the French Public Health Insurance point of view according to the French Diagnosis-Related Group prospective payment system an…

AdultMalesafetymedicine.medical_specialtyCarcinoma HepatocellularCost effectivenesschemoembolisationCost-Benefit AnalysisAntineoplastic AgentsTreatment failureDrug CostsEthiodized OilInternal medicinemedicineOverall survivalHumansPharmacology (medical)Chemoembolization Therapeuticcost-effectivenessAgedRetrospective StudiesPharmacologyAged 80 and overDrug CarriersDrug eluting beadsPublic health insurancebusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseasePrognosisMicrospheres3. Good healthSurgerySurvival RateTreatment OutcomeMedian timeDoxorubicinHepatocellular carcinoma[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyFemaleProspective payment systembusinessIdarubicin
researchProduct

Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years

2004

Background & aims: Increased morbidity and mortality from liver disease have been reported in chronic hepatitis B surface antigen (HBsAg) carriers, but data on survival are equivocal. To assess the impact of hepatitis B virus (HBV) infection on survival and liver-related complications, we re-evaluated, after a mean follow-up of 30 years, a cohort of 296 blood donors excluded from donation 30 years ago when HBsAg screening became mandatory. Methods: Clinical and ultrasound examination and biochemical and virologic tests were performed. The cause of death was recorded and survival was compared with a control population of 157 HBV-negative blood donors selected at baseline. Results: Thirty-two…

AdultMalevirus DNAmedicine.medical_specialtyHBsAgHepatitis B virusCirrhosisBlood Donorsmedicine.disease_causeGastroenterologyserum HBVCohort StudiesLiver diseaseHepatitis B ChronicInternal medicinemedicineHumansProspective StudiesSurvival analysisCause of deathAgedHepatitis B virusHepatitis B Surface AntigensHepatologybusiness.industryalcoholGastroenterologyHepatitis BMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseaseshepatitis B surface antigenItalygamma glutamyltransferaseHepatocellular carcinomaImmunologyCarrier StateFemalebusinessFollow-Up Studies
researchProduct

“Preemptive” Live Donor Liver Transplantation for Fibrolamellar Hepatocellular Carcinoma: A Case Report

2008

Fibrolamellar (FL) hepatocellular carcinoma (HCC) is a distinctive form of primary HCC that occurs principally in children and young adults. Although liver transplantation is not contraindicated for FL-HCC, noncirrhotic patients with large HCC tumors (including FL-HCCs) are not prioritized. Although hepatic resection is considered to be the primary treatment for FL-HCC, living donor liver transplantation is evolving into a potentially better alternative. Herein we have reported successful "preemptive" living donor liver transplantation for presumed recurrence of FL-HCC after an extended right hepatectomy with resection and synthetic graft replacement of the inferior vena cava.

Adultmedicine.medical_specialtyCarcinoma HepatocellularLive donormedicine.medical_treatmentMedizinLiver transplantationInferior vena cavaGastroenterologyInternal medicineLiving DonorsmedicineHumansYoung adultneoplasmsTransplantationbusiness.industryLiver NeoplasmsFactor VCancermedicine.diseaseCombined Modality Therapydigestive system diseasesSurgeryRadiographyFibrolamellar hepatocellular carcinomamedicine.veinHepatocellular carcinomaMutationFemaleSurgerySafetyLiver cancerbusinessTransplantation Proceedings
researchProduct

Fully robotic left hepatectomy for malignant tumor: technique and initial results

2018

Robotic liver surgery has been considered as a unique opportunity to overcome the traditional limitations of laparoscopy; thus, it can potentially extend the indications of minimally invasive liver surgery. From April 2015 to May 2017, 35 patients underwent fully robotic left hepatectomy. The mean operative time was 315 min (200-445 min) and the mean estimated blood loss was 245 ml (125-628 ml). Pringle maneuver was required in six cases. Cancer was the indication for surgery in all patients (14 liver metastases, 18 hepatocellular carcinomas and 3 cholangiocarcinomas). There were one to four lesions in a patient and the mean lesion size was 39.2 mm (15-85 mm). The average length of hospital…

Adultmedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentOperative TimeBlood Loss Surgical030230 surgeryCholangiocarcinomaLesion03 medical and health sciences0302 clinical medicineRobotic Surgical ProceduresBlood lossMinimally invasive surgerymedicineHepatectomyHumansRobotic left hepatectomyLaparoscopyAgedLiver resectionmedicine.diagnostic_testbusiness.industryMortality rateLiver NeoplasmsMargins of ExcisionCancerPerioperativeLength of StayMiddle Agedmedicine.diseaseRobotic liver resectionSurgerySettore MED/18 - Chirurgia GeneraleTreatment OutcomeLiver030220 oncology & carcinogenesisOperative timeFemaleSurgeryHepatectomymedicine.symptombusinessUpdates in Surgery
researchProduct

Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1.

2006

The hepatic carcinogen aflatoxin B1 (AFB1) is metabolized in the liver by at least four different P450s, all of which exhibit large interindividual differences in the expression levels. These differences could affect the individual risk of hepatocellular carcinoma (HCC). We investigated the metabolism of AFB1 in a panel of 13 human liver microsomal preparations using a hepatic abundance model, which takes into account the specific kinetic parameters and the expression levels of these P450s. We found a 12-fold variability in the production rate of the carcinogenic metabolite AFB1-8,9-epoxide (AFBO) and a 22-fold variability in the production of the detoxification product AFQ1. The ratio betw…

AflatoxinAflatoxin B1MetabolitePharmacologyToxicology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCytochrome P-450 Enzyme SystemmedicineCytochrome P-450 CYP3AHumansCarcinogenBiotransformationChromatography High Pressure Liquid030304 developmental biologychemistry.chemical_classification0303 health sciencesPrimary metaboliteGeneral MedicineMetabolismmedicine.diseaseEnzymeBiochemistrychemistryLiver030220 oncology & carcinogenesisHepatocellular carcinomaMicrosomeCarcinogensChemical research in toxicology
researchProduct